PolyPid to Announce Q2 2024 Financial Results and Operational Highlights on August 14, 2024

PETACH TIKVA, Israel, July 31, 2024 -- PolyPid Ltd. (Nasdaq: PYPD), a late-stage biopharmaceutical company focusing on enhancing surgical results, has announced plans to release its financial results and operational highlights for the second quarter of 2024. The report will be published before the U.S. financial markets open on Wednesday, August 14, 2024. Alongside the publication, the company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide updates on its business operations.

PolyPid encourages participants to register for the conference call at least 5 minutes before it begins to ensure a smooth connection. For those not intending to ask questions, listening via the webcast is recommended.

PolyPid Ltd. is a biopharmaceutical company in the late stages of development, dedicated to improving surgical outcomes. They achieve this through their proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology, which allows for the local administration of controlled, prolonged-release therapeutics. This technology pairs with Active Pharmaceutical Ingredients (APIs) to enable precise drug delivery at optimal release rates over periods ranging from several days to months.

The company's leading product candidate, D-PLEX100, is currently in Phase 3 clinical trials focused on preventing abdominal colorectal surgical site infections. Furthermore, PolyPid is in the preclinical stages of testing OncoPLEX for treating solid tumors, starting with glioblastoma.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!